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Abstract
Background:  Recognition of microbial products through Toll-like receptors (TLRs) initiates
inflammatory responses orchestrated by innate immune cells such as dendritic cells (DCs). As these
cells are patrolling mucosal surfaces, a portal of entry for various pathogens including human
immunodeficiency virus type-1 (HIV-1), we investigated the impact of TLR stimulation on
productive HIV-1 infection of DCs and viral spreading to CD4+ T cells.
Results: We report here that engagement of TLR2 on DCs increases HIV-1 transmission toward
CD4+ T cells by primarily affecting de novo virus production by DCs. No noticeable and consistent
effect was observed following engagement of TLR5, 7 and 9. Additional studies indicated that both
HIV-1 infection of DCs and DC-mediated virus transmission to CD4+ T cells were reduced upon
TLR4 triggering due to secretion of type-I interferons.
Conclusion: It can thus be proposed that exposure of DCs to TLR2-binding bacterial constituents
derived, for example, from pathogens causing sexually transmissible infections, might influence the
process of DC-mediated viral dissemination, a phenomenon that might contribute to a more rapid
disease progression.
Background
Myeloid dendritic cells (mDCs) play a dominant role in
the induction and regulation of the adaptive immune
response. It has been demonstrated that immature mDCs
reside in submucosal tissues that are in contact with the
external environment. These cells act as sentinels and con-
tinuously patrol the surrounding environment to detect
potential invaders. Upon encountering a pathogen, they
scavenge and internalize the intruder before migrating to
the draining lymph nodes, where they present processed
antigens to CD4+  T cells, thus initiating an immune
response [1].
Pathogens express signature motifs better known as path-
ogen-associated molecular patterns (PAMPs), which are
recognized by immature mDCs through several pathogen-
recognition receptors [2,3] such as Toll-like receptors
(TLRs) [4,5]. These specialized receptors provide a first
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line of defence against a pathogen attack and rapidly acti-
vate defence signalling pathways following initial infec-
tion. TLRs are considered as playing a crucial role in the
switch from innate to adaptive immunity in mammals. To
date, at least 10 distinct TLRs have been characterized in
humans and they are classified according to which PAMPs
they recognize [6]. For example, TLR2, 4 and 5 mainly rec-
ognize bacterial components, whereas TLR3, 7, 8 and 9
detect nucleic acids derived from microorganisms [7]. The
detection of PAMPs by TLRs triggers biochemical events
resulting in NF-κB activation and induction of a pro-
inflammatory response. The latter phenomenon is charac-
terized by the migration of immature mDCs to secondary
lymphoid organs where they mature and efficiently
present the nominal antigen to CD4+ T cells [1,8-10].
Due to their strategic localization in mucosal epithelia,
immature mDCs are among the first cells to encounter
HIV-1 after sexual transmission [11-14], and they are
thought to play a crucial role during the initial stages of
virus infection and dissemination [15]. HIV-1 can produc-
tively infect immature mDCs, although not at a rate suffi-
cient to affect viral load. Nonetheless, this cell
subpopulation contributes to viral propagation, as they
migrate to lymph nodes, where they efficiently transfer
newly produced virions to CD4+  T cells through the
immunological synapse [16]. This specific type of virus
propagation is called transfer in cis  or late transfer.
Another type of transfer can take place when virions,
either surface-bound or inside intracellular vesicles, are
released following an intimate contact between DCs and
CD4+ T cells. This type of virus transmission is termed
transfer in trans or early transfer [17,18]. Thus, by captur-
ing HIV-1 at sites of viral entry into the body and transfer-
ring viruses to CD4+ T cells, immature mDCs may be
critical to the process of HIV-1 transmission.
The impact of microbial products on HIV-1 pathogenesis
was highlighted by recent studies showing that acute HIV-
1 infection increases the gut permeability favouring trans-
location of microbial products through the intestinal bar-
rier into submucosal lamina propria and then mesenteric
lymph nodes and bloodstream [19-23]. This phenome-
non causes systemic immune activation that will in turn
promote HIV-1 infection and spreading. In addition to
HIV-1, several other factors can lead to enhanced micro-
bial translocation across the intestinal barrier including
direct injury of epithelial cells by others pathogens or tox-
ins that increase the gut permeability. Translocation of
microbial products can also increase activation of mDCs
in the lamina propria through TLR stimulation. Some
studies have previously monitored the impact of TLR
stimulation on DCs. For example, activation of DCs by
lipoproteins derived from Porphyromonas gingivalis and
Mycoplasma fermentans was found to be mediated by TLR2
[24,25]. Moreover, stimulation of TLR4, 7 and 9 in DCs
has been reported to lead to secretion of type-I interferons
(IFNs) such as IFNα and IFNβ, two soluble factors that
can repress HIV-1 replication. It has been demonstrated
that type-I IFNs display pleiotropic effects which affect
several steps in the virus life cycle from the initial viral
uptake to the release of newly formed virions [26-29].
However, we are only beginning to study the putative
effect(s) of bacterial products that can bind TLRs in DCs
in the context of HIV-1 infection [30,31]. It has been
recently reported that productive HIV-1 infection of
immature monocyte-derived DCs is enhanced following
TLR2 engagement by Neisseria gonorrhoeae [30].
Considering the key role played by mDCs in the patho-
genesis of HIV-1 infection, that mDCs are constantly
exposed to microbial components derived from different
pathogens and commensal microorganisms upon micro-
bial translocation, and knowing that this phenomenon
accentuates HIV-1 infection and spreading, we investi-
gated whether TLR2, 4, 5, 7 and 9 agonists can directly
modulate the ability of immature monocyte-derived DCs
(IM-MDDCs), which are considered as myeloid-like DCs,
to be productively infected with HIV-1 and transfer virus
to susceptible CD4+ T cells.
Results
In this study, we made use of agonists specific for various
TLRs known to be expressed in DCs, namely Pam3Csk4
and LTA for TLR2, LPS for TLR4, flagellin for TLR5, R837
for TLR7, and bacteria-derived unmethylated DNA for
TLR9. Our experiments were all performed with immature
DCs because these cells have been proposed to be among
the first potential targets that encounter HIV-1 during sex-
ual transmission and also because virus replication is very
inefficient in mature DCs. Importantly, IM-MDDCs were
selected based on the observation that their characteristics
resemble those of the different DC subsets found in vivo
(e.g. mDCs, immature dermal DCs and interstitial DCs)
[32-34], including their TLR expression patterns [35].
TLR2 triggering affects primarily de novo virus production 
in IM-MDDCs
To define whether TLR stimulation can affect HIV-1 trans-
fer, IM-MDDCs were first treated for only 2 hours with
one of the tested TLR agonists before pulsing with the R5-
using HIV-1 strain NL4-3/Balenv. Thereafter, the cell-virus
mixture was co-cultured with autologous CD4+ T cells and
cell-free supernatants were harvested at 2, 3 and 6 days
post-co-culture (dpcc) to measure virus transfer. As
depicted in Fig. 1A (left panel), transmission of HIV-1 was
markedly increased upon TLR2 stimulation at 2 dpcc,
whereas a diminution was seen following LPS-mediated
engagement of TLR4. The kinetics of virus production in
the co-cultures revealed that TLR2 and 4 triggering affectsRetrovirology 2009, 6:42 http://www.retrovirology.com/content/6/1/42
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an early step(s) in the process of virus transfer since the
modulatory effects were disappearing over time (small
insert in the left panel). Engagement of TLR5, 7 and 9 did
not affect the DC-mediated propagation of HIV-1. Similar
patterns of HIV-1 transfer were obtained when experi-
ments were conducted with multiple independent donors
(Fig. 1A, right panel). Next, we evaluated whether the
observed modulation of virus transfer could be attributa-
ble to de novo virus production by IM-MDDCS (i.e. late
transfer). This issue was solved by adding the inhibitor of
reverse transcription Efavirenz (EFV) before pulsing IM-
MDDCs with virions. Results illustrated in Fig. 1B indicate
that the TLR2-mediated signal transduction pathway was
affecting primarily direct productive infection of IM-
TLR2 and 4 triggering modulates HIV-1 transfer between IM-MDDCs and CD4+ T cells Figure 1
TLR2 and 4 triggering modulates HIV-1 transfer between IM-MDDCs and CD4+ T cells. A) IM-MDDCs were 
either left untreated (mock) or stimulated for 2 hours with the following TLR agonists: Pam3Csk4 (5 μg/ml), LPS (0.1 μg/ml), 
flagellin (5 μg/ml), R837 (5 μg/ml) and unmethylated DNA (5 μg/ml). Cells were then pulsed with NL4-3/Balenv and co-cultured 
with autologous CD4+ T cells. Finally cell-free supernatants were harvested at 2, 3 and 6 days post-coculture (dpcc) and the 
viral content was assessed by a p24 assay. Data depicted in the left panel represent the mean ± standard deviations of quadru-
plicate samples from a representative single donor at 2 dpcc, whereas the kinetics of virus production for the same donor are 
displayed in the small insert. Results from multiple different donors are illustrated in the right panel (2 dpcc) (**: P < 0.01; ***: 
P < 0.001). B) IM-MDDCs were initially either left untreated or treated with EFV. Thereafter, cells were either left untreated 
or treated with Pam3Csk4. Data shown represent the mean ± standard deviations of quadruplicate samples from a single 
donor at 2 dpcc and are representative of 8 distinct donors. C) A similar experimental approach was used except that transfer 
studies were carried out with the X4-tropic strain NL4-3. Data shown represent the mean ± standard deviations of quadrupli-
cate samples from a single donor at 2 dpcc and are representative of 3 different donors.
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MDDCs (i.e. late transfer due to newly formed viral enti-
ties) since the Pam3Csk4-dependent augmentation in
virus transfer was almost totally abrogated upon treat-
ment with EFV. Although it is well accepted that primary
HIV-1 infection is caused by R5-tropic viruses, some
experiments were also carried out with an X4-using isolate
of HIV-1 (i.e. NL4-3). The TLR2-mediated enhancement
in virus transfer was also seen with the X4-tropic variant as
well as the reduction of HIV-1 propagation by the TLR4
agonist (Fig. 1C). The effect of the studied TLR agonists on
cell viability was also monitored using the fluorescent
cytotoxic MTS assay. Cell viability was not affected by the
studied TLR ligands used at concentrations known to
modulate the DC-mediated transfer of HIV-1 (data not
shown).
To corroborate the role played by TLR2/4 triggering in late
virus transfer, we measured the effect of TLR2 and 4 lig-
ands upon acute virus infection of IM-MDDCs. As
expected, virus production in IM-MDDCs cultured alone
was much lower than in co-cultured cells (Fig. 2A, left
panel). Interestingly, replication of HIV-1 in IM-MDDCs
was still enhanced by the TLR2 ligand at an early time
point following virus infection while engagement of TLR4
led to a potent inhibition of virus production. Again, flag-
ellin (TLR5), R837 (TLR7) and unmethylated DNA
(TLR9) showed no noticeable and consistent effect on
HIV-1 replication in IM-MDDCs cultured alone (data not
shown). The TLR2-mediated increase in de novo virus pro-
duction in IM-MDDCs was no longer seen in presence of
EFV (Fig. 2A, right panel), thus confirming that the effect
was primarily due to cis replication in the DC population.
To provide additional in vivo significance to our findings
and considering that Pam3Csk4 is a synthetic TLR2 ago-
nist, we also tested the effect of the prototypic TLR2 ago-
nist LTA that was isolated directly from Staphylococcus
De novo virus production in IM-MDDCs is affected by TLR2 and 4 engagement Figure 2
De novo virus production in IM-MDDCs is affected by TLR2 and 4 engagement. (A) IM-MDDCs were either left 
untreated (mock) or stimulated for 2 hours with the listed TLR agonists. Thereafter, cells were washed twice and pulsed with 
NL4-3/Balenv. IM-MDDCs were either left untreated (left panel) or treated with EFV (right panel) before addition of TLR ago-
nists. Supernatants were harvested at 3, 6 and 9 days post-infection (dpi) and the viral content was monitored by a p24 test. 
Data depicted represent the mean ± standard deviations of quadruplicate samples from a single donor and are representative 
of 3 different donors. (B) A similar experimental strategy was used except that cells were either left untreated or exposed to 
the listed TLR2 ligands. Data shown represent the mean ± standard deviations of quadruplicate samples from two different 
donors (3 dpi). (C) Cells were either left untreated (mock) or stimulated for 2 hours with the listed TLR2 agonists. Thereafter, 
cells were washed twice and pulsed with the clinical HIV-1 isolate 93TH054. Supernatants were harvested at 5 dpi and the viral 
content evaluated by a p24 test. The data shown represent the mean of quadruplicate samples from 2 different donors.
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aureus. Results depicted in Fig. 2B illustrate that both TLR2
agonists, i.e. synthetic and isolated bacterial constituent,
can increase virus production in IM-MDDCs cultured
alone. To more closely parallel natural conditions, acute
infection experiments were also conducted with a R5-
tropic field isolate of HIV-1 (i.e. 93TH054). As shown in
Fig. 2C, both Pam3Csk4 and LTA were able to enhance
replication of the clinical isolate 93TH054 in IM-MDDCs.
TLR2, 4 and 5 triggering results in nuclear translocation of 
NF- B
The transcription factor NF-κB is recognized as a powerful
inducer of HIV-1 transcription and gene expression due to
the presence of two NF-κB binding sites located within the
enhancer domain. Therefore, we next studied the possible
TLR2-, 4-, 5-, 7- and 9-mediated induction of NF-κB by
analyzing the phosphorylation state of IκBα, a sign of NF-
κB activation. IM-MDDCs were stimulated with the stud-
ied TLR agonists for 0, 2, 5, 15 and 30 minutes and lysed.
Phosphorylation and degradation of IκBα were moni-
tored by western blotting analyses. Data shown in Fig. 3
demonstrate that IκBα is rapidly phosphorylated follow-
ing TLR2, 4 and 5 triggering. For example, a band specific
for the phosphorylated form of IκBα was detected follow-
ing 5 minutes of exposure of IM-MDDCs to the TLR2 ago-
nist. This rapid IκBα phosphorylation was accompanied
by a fast and extensive degradation of IκBα at 5 and 15
minutes. A weaker but detectable phosphorylation of
IκBα was also seen upon engagement of TLR4, but this
time, 15 minutes following treatment with the agonist.
The degradation of IκBα was also delayed, as compared to
TLR2 triggering, since the protein started to disappear
only 15 minutes after treatment. Furthermore, engage-
ment of TLR5 resulted in a pattern of IκBα phosphoryla-
tion and degradation comparable to the situation
prevailing in the presence of TLR2 ligand. TLR7 and 9 trig-
gering resulted in little impact on IκBα, which is not sur-
prising considering the reported low expression levels of
TLR7 and 9 in IM-MDDCs [35,36].
Soluble factors are released upon engagement of the 
tested TLRs in IM-MDDCs
Upon exposure to some microbial products, DCs can pro-
duce pro-inflammatory cytokines and chemokines that
influence the nature of the immune response. The func-
tionality of the studied TLRs was assessed by measuring
the production of some defined soluble factors. As illus-
trated in Fig. 4, TLR2, 4 and 5 ligands induce significant
secretion of IL-6, TNF-α, MIP-1α and RANTES. The IL-
12p70, which is the bioactive form of IL-12 involved in a
TH1 response, has only been detected in supernatants har-
vested from LPS-stimulated IM-MDDCs. A weak produc-
tion of TNF-α, MIP-1α and MIP-1β was also seen when
using TLR7 and 9 agonists.
TLR2 and 4 triggering modulates an early step in HIV-1 
replication
To provide information on the mechanism(s) by which
TLR2 engagement can promote virus production, IM-
MDDCs were either treated first with the TLR2 agonist
prior to virus infection or, alternatively, pulsed first with
HIV-1 before Pam3Csk4 treatment. As shown in Fig. 5A, a
TLR2-mediated enhancement of virus replication was
seen only when stimulation took place before HIV-1
infection, thus suggesting that the signalling cascade trig-
gered by the agonist acts most likely at an early step in the
virus life cycle. To confirm that TLR2 triggering is not
affecting more downstream events in HIV-1 replication
(i.e. subsequent to integration), IM-MDDCs were infected
with single-cycle reporter virus pseudotyped with VSV-G
for a time period sufficient to allow integration of the viral
genetic material within host genome (i.e. 48 hours) [37].
The use of such viruses prevents re-infection events and
NF-κB is activated in IM-MDDCs following TLR2, 4 and 5  triggering Figure 3
NF-κB is activated in IM-MDDCs following TLR2, 4 
and 5 triggering. Cells were either left untreated (mock) 
or stimulated for 0, 2, 5, 15 and 30 min with the listed TLR 
ligands. Cells were then lysed and proteins were loaded on a 
12% SDS-polyacrylamide gel, transferred to a membrane, and 
revealed by anti-phospho-IκBα, anti-IκBα, or anti-actin. Data 
from a single donor representative of 4 different donors are 
displayed.
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Some cytokines and chemokines are secreted following engagement of TLRs Figure 4
Some cytokines and chemokines are secreted following engagement of TLRs. IM-MDDCs were either left 
untreated or stimulated for 8 and 24 hours with the listed TLR ligands. Cell-free supernatants were harvested and analyzed 
with a Bio-Plex assay that can detect all the indicated soluble factors. The results shown are representative of two separate 
experiments performed with two distinct donors.
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bypasses the natural mode of HIV-1 entry (namely via a
CD4- and CCR5-dependent pathway) [38]. Thereafter,
cells were treated with Pam3Csk4 before monitoring the
virus-directed luciferase activity. Results from Fig. 5B dem-
onstrated that integrated viral DNA was not activated
upon engagement of TLR2, thus corroborating that TLR2
triggering is primarily affecting an early event in the virus
life cycle (i.e. before virus integration).
To shed light on the mechanism(s) by which TLR2 and 4
triggering can affect de novo virus production, the extent of
virus entry was quantified in IM-MDDCs. Data displayed
in Fig. 6 indicate that virus internalization was increased
at a comparable level by TLR2 and 4 agonists as compared
to untreated cells. Since there is no linear relationship
between internalization of viral particles in IM-MDDCs
and productive infection, we investigated whether reverse
transcription and integration processes are affected by a
treatment with Pam3Csk4 and LPS. This issue was
addressed through the use of a quantitative real-time PCR
assay that has been described previously by Zack and col-
leagues [39]. Results displayed in Fig. 7A indicate that the
amounts of early reverse transcripts were increased by a
treatment with the TLR2 agonist while a diminution was
seen with LPS. A similar trend was made when measuring
the levels of late reverse transcripts (Fig. 7B). Integration
of viral DNA was also promoted by the TLR2 agonist (Fig.
7C), whereas this process was significantly reduced upon
a treatment with the TLR4 ligand LPS.
TLR4 stimulation induces secretion of type-I IFNs
Knowing that TLR4 stimulation can lead to secretion of
type-I IFNs (i.e. IFNα and IFNβ), we next wanted to see
whether the observed TLR4-dependent diminution in
virus replication was attributable to these antiviral agents.
To demonstrate the participation of type-I IFNs in the LPS-
dependent modulatory effect on virus production in IM-
MDDCs, we performed experiments with HEK-Blue™
IFNα/β indicator cells. Results depicted in Fig. 8A indicate
that the TLR4 ligand LPS acted as a strong inducer of
IFNα/β in IM-MDDCs while TLR2, 5, 7 and 9 triggering
did not result in the secretion of type-I IFNs. To confirm
the involvement of the LPS-mediated production of type-
I IFNs in the observed diminution of HIV-1 production in
IM-MDDCs, we performed studies with B18R, a vaccinia
virus-derived soluble receptor that blocks the effect of bio-
logically functional type-I IFNs (e.g. IFNα, IFNβ and
IFNω). Results depicted in Fig. 8B indicate that the TLR4-
mediated reduction in de novo virus production seen in
IM-MDDCs was indeed associated with secretion of type-
I IFNs.
Discussion
It is now well established that the majority of HIV-1 infec-
tions are acquired sexually. Considering that co-infections
exacerbate the risk for HIV-1 acquisition, it is relevant to
understand how microbial constituents can modulate the
process of virus infection and create a more favourable
environment for HIV-1 dissemination. Immature mDCs
residing in mucosal tissues are thought to be one of the
TLR2 stimulation influences an early step in HIV-1 life cycle Figure 5
TLR2 stimulation influences an early step in HIV-1 
life cycle. A)IM-MDDCs were either left untreated (mock) 
or stimulated for 2 hours with the TLR2 agonist Pam3Csk4 
(5 μg/ml) before or after exposure for 1 hour to NL4-3/
Balenv. Supernatants were harvested at 72 hours post-infec-
tion and the viral content was evaluated by a p24 test. B) 
Cells were infected with VSV-G pseudotyped reporter 
viruses for 2 hours, washed twice and put in culture for 48 
hours. Next, IM-MDDCs were either left untreated (mock) 
or stimulated for 2 hours with Pam3Csk4. Cells were then 
washed twice, cultured for 48 hours and lysed to monitor 
luciferase activity (expressed in relative light units/RLU). The 
data shown represent the mean ± standard deviations of 
quadruplicate samples from a single donor and are repre-
sentative of 3 distinct donors.
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TLR2 and 4 triggering increases viral entry in IM-MDDCs Figure 6
TLR2 and 4 triggering increases viral entry in IM-
MDDCs. A) IM-MDDCs were either left untreated (mock) 
or treated with TLR2 and 4 ligands for 2 hours and washed 
twice. Then, cells were pulsed with NL4-3/Balenv for 15, 30 
and 60 min at 37°C. Next, the virus-cell mixture was washed 
extensively with PBS and trypsinized to remove uninternal-
ized virus. Finally, cells were lysed and the p24 contents were 
measured by ELISA. Numbers depicted above bars represent 
fold increase relative to p24 levels in untreated control cells 
(considered as 1). The data shown represent the mean ± 
standard deviations of triplicate samples from 3 different 
donors.
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Early steps in HIV-1 replication are modulated by TLR2 and 4 agonists Figure 7
Early steps in HIV-1 replication are modulated by TLR2 and 4 agonists. IM-MDDCs were either left untreated or 
stimulated for 2 hours with the TLR2 or 4 agonist. Cells were next pulsed with NL4-3/Balenv for 1 hour, washed twice and 
incubated at 37°C. Total DNA was extracted at 6, 24 or 48 hours post-infection and used for the detection and quantification 
of early reverse transcripts (A), late reverse transcripts (B) and integrated viral DNA (C) using a real-time PCR method. The 
number of HIV-1 copies was determined by a standard curve prepared with the NL4-3/Balenv vector. Data depicted in panels 
(A) and (B) represent the mean ± standard deviations of duplicate samples representative of two distinct donors whereas 
those illustrated in panel (C) represent the mean ± standard deviations of duplicate samples from 5 (Pam3Csk4) or 3 separate 
donors (LPS) (*: P < 0.05).
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first cell types encountering HIV-1 during sexual transmis-
sion. These cells can efficiently capture HIV-1 and depend-
ing on the receptors used and the surrounding
environment, several distinct processes can occur concur-
rently. For example, viruses can directly bind CD4 and the
appropriate co-receptor on the plasma membrane of
immature mDCs leading to a cytosolic delivery of viral
material and productive infection [40,41]. Alternatively,
incoming virions can either remain in an infectious state
within intracellular vesicles or be associated in membrane
protrusions and microvilli found on the plasma mem-
brane before a subsequent transmission through the viro-
logical synapse [17,42,43]. Internalized viruses can also
be degraded by lysosomal enzymes inside the endosomal
machinery [44]. It is thus expected that exposure of imma-
ture mDCs to stimuli such as microbial-derived PAMPs
might influence the virus uptake pathway and the even-
tual fate of HIV-1 in these cells.
In the present study, we investigated whether TLR2, 4, 5,
7 and 9 triggering can modulate the ability of IM-MDDCs
to capture, internalize, replicate and transfer HIV-1. We
first assessed the capacity of the tested agonists to modu-
late HIV-1 transmission. We found that the TLR2 ligand
Pam3Csk4 increased virus transfer from IM-MDDCs to
autologous CD4+ T cells, whereas the process remains
almost unaffected upon TLR5, 7 and 9 triggering. Moreo-
ver, we report that the process of HIV-1 propagation in a
co-culture system was diminished by TLR4 engagement.
The fact that the TLR2- and 4-mediated effect on HIV-1
propagation was seen only at an early time point follow-
ing initiation of the co-culture (i.e. 2 days) and was rap-
idly lost thereafter is indicative of a modulatory effect on
intricate interactions between HIV-1 and IM-MDDCs. The
loss of the TLR2- and 4-dependent effect on HIV-1 transfer
at later time points following initiation of the culture is
due to a rapid and massive spreading of HIV-1 in the
CD4+ T cell population. The validity and clinical relevance
of our findings are provided by three sets of experiments.
First, the TLR2-mediated augmentation in virus produc-
tion was detected when using both a synthetic (i.e.
Pam3Csk4) and a more natural TLR2 agonist (i.e. LTA).
Second, similar findings were made when viral infection
studies were carried out with a field isolate of HIV-1.
Third, the TLR2-dependent up-regulatory effect on HIV-1
propagation was seen with both R5- and X4-using virions.
To define the exact contribution of de novo virus produc-
tion from IM-MDDCs in the TLR2-dependent up-regula-
tory effect on HIV-1 transfer, co-culture experiments were
performed in presence of EFV. According to our results, it
can be proposed that TLR2 triggering is mostly affecting
the direct productive infection of IM-MDDCs with HIV-1
since treatment with EFV reduced the level of viral transfer
close to that observed for untreated cells. Acute infection
studies performed with IM-MDDCs confirmed that TLR2
engagement is modulating primarily de novo virus produc-
tion in this cell type. Our findings are perfectly in line with
a recent study showing that the TLR2 ligand Pam3Csk4
strongly enhanced HIV-1 transmission [45]. However, the
reported TLR2-mediated enhancement in virus transmis-
sion was due to a more important HIV-1 capture and not
to a superior virus replication in this cell type as we dem-
onstrate here in the present work. Differences in experi-
mental methodologies may account for the discrepant
results. Indeed, the experimental cell system used by de
Jong and colleagues consisted of human epidermal sheet
explants that contained resident Langerhans cells. It
should be noted that Langerhans cells and IM-MDDCs are
quite distinct with respect to their cell surface expression
patterns, migratory capacity, endocytic ability and immu-
nological functions [46]. Our results are also consistent
with findings published by Zhang and colleagues who
have demonstrated that HIV-1 replication in IM-MDDCs
is promoted by Neisseria gonorrhea mainly through
engagement of TLR2 by the peptidoglycan of the gono-
cocci [30]. However, in this study, IM-MDDCs were first
exposed for 48 hours to bacteria or other Neisseria gonor-
rhea constituents before HIV-1 pulsing as opposed to 2
hours in the present study. It is expected that the DC pop-
TLR4-mediated decrease in de novo virus production  involves type-I IFNs Figure 8
TLR4-mediated decrease in de novo virus production 
involves type-I IFNs. A) IM-MDDCs were either left 
untreated (mock) or stimulated for 6 hours with the listed 
TLR ligands. Cell-free supernatants were harvested and the 
levels of IFNα/β were quantified through the use of HEK-
Blue™ IFNα/β cells. The data shown represent the mean ± 
standard deviations of quadruplicate samples from a single 
donor. B) IM-MDDCs were either left untreated (mock) or 
stimulated for 2 hours with the TLR4 ligand LPS. Cells were 
then washed twice, pulsed with NL4-3/Balenv and cultured in 
absence or presence of B18R (0.1 μg/ml). Supernatants were 
harvested at 72 hours post-infection and the viral content 
was evaluated by a p24 test. The data shown represent the 
mean ± standard deviations of quadruplicate samples from a 
single donor and are representative of 4 different donors.
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ulation used by Zhang and co-workers is displaying a
more mature phenotype than what we have used in our
experiments.
Sensing PAMPs through TLRs usually triggers signalling
cascades resulting in the activation of the transcription
factor NF-κB and the induction of pro-inflammatory
responses, which are required to fight the invaders. It is
well known that induction of NF-κB drives HIV-1 tran-
scription and production of newly synthesized virions in
both CD4+ T lymphocytes and monocytes/macrophages
(reviewed in [47,48]). Although the exact role played by
NF-κB in the process of acute HIV-1 infection of IM-
MDDCs remains unclear, we hypothesized that it is the
same for all myeloid lineage cells. In order to define if the
tested TLR agonists can trigger signalling cascades result-
ing in NF-κB activation, we measured phosphorylation
and ensuing degradation of the natural repressor of NF-κB
(i.e. IκBα). Our results indicate that IκBα is rapidly phos-
phorylated following TLR2 stimulation. Although DC-
mediated virus transfer was not modulated upon TLR5
triggering, a potent induction of NF-κB was seen follow-
ing ligation of TLR5. It can thus be proposed that there is
no direct relationship between these two events. This pos-
tulate is confirmed by our findings that TLR4 signalling
results in a quite different outcome since a reduced HIV-1
propagation was detected concomitantly with an induc-
tion of NF-κB. Moreover, our observations that the NF-κB-
regulated cytokine TNF-α is induced, albeit at different
levels, by all studied TLR ligands supports this hypothesis.
Nevertheless, based on results obtained with a Bio-Plex
assay, it is obvious that TLR2 and 4 triggering in IM-
MDDCs is more efficient than TLR5, 7 and 9 stimulations
as evidenced by the higher production of IL-6, TNF-α and
RANTES.
Knowing that TLR4 stimulation can activate pathways
resulting in both NF-κB activation and secretion of type-I
IFNs [49,50], we hypothesized that the observed TLR4-
mediated inhibition of virus production in IM-MDDCs is
linked to the production of such soluble factors. It has
already been reported that exposure of macrophages to
LPS or gonococcal lipooligosaccharide reduces HIV-1 rep-
lication through a mechanism relying on production of
type-I IFNs [51-53]. We showed here the direct involve-
ment of type-I IFNs in TLR4-dependent decrease in HIV-1
replication through the use of the recombinant B18R pro-
tein and HEK-Blue™ IFNα/β cells. Interestingly, data from
HEK-Blue™ IFNα/β cells indicate that LPS treatment leads
to a rapid production of type-I IFNs (i.e. as early as 2 hours
following exposure to the TLR4 ligand) (data not shown)
reaching a peak at 6 hours. Given that IM-MDDCs were
inoculated with HIV-1 at 2 hours after addition of LPS, it
can be proposed that the initial steps in the virus life cycle
are affected by IFNα and/or β. Data from studies per-
formed with B18R suggest that secretion of type-I IFNs,
which is seen following TLR4 triggering, may counteract
the likely positive effect of NF-κB on virus gene expres-
sion. Surprisingly, the process of virus entry was enhanced
upon LPS treatment. It is likely that the positive impact of
TLR4 ligand in HIV-1 entry is totally neutralized by the
antiviral activity of IFNα/β.
The LPS-mediated diminution in HIV-1 transmission con-
trasts with some previous studies reporting that the DC-
mediated virus transfer is enhanced upon LPS treatment
[16,54-61]. However, in these studies, IM-MDDCs were
exposed to LPS for at least 24 to 48 hours before HIV-1
pulsing and the initiation of the co-culture with CD4+ T
cells. This time period is sufficient to induce a complete
maturation phenotype in DCs. In our study, we treated
IM-MDDCs with LPS for only 2 hours, which is not suffi-
cient per se to induce DC maturation. The present work
was aimed at measuring the impact of TLR-mediated stim-
ulation that is not long enough to obtain DC maturation
but sufficient to trigger some biological responses such as
cytoskeleton remodelling and an increase in macropinoc-
ytosis [62]. Interestingly, the shape of LPS-stimulated DCs
is completely different at 2 and 24 hours following stimu-
lation. Indeed, DCs acquire an elongated form and stick at
the bottom of the well after a 2 hours treatment period
whereas they form cellular aggregates remaining in sus-
pension after 24 hours of treatment with LPS (unpub-
lished data). Therefore, it is not surprising to obtain
different results with the two conditions in regard to DC-
mediated trans-infection of CD4+ T cells with HIV-1. This
is confirmed by previous findings since the efficiency of
HIV-1 transmission is enhanced following maturation of
DCs [8,16,54,63].
Considering the up-regulatory effect of NF-κB with regard
to HIV-1 transcription and the potent induction of this
transactivator by TLR2 stimulation, we thought that the
TLR2-mediated augmentation in de novo virus production
by IM-MDDCs would be similar if TLR2 triggering would
occur after viral uptake. Surprisingly, virus production was
not affected under such experimental conditions. This
suggests that engagement of TLR2 in IM-MDDCs carrying
integrated viral DNA is not sufficient per se to drive HIV-1
gene expression. Therefore, the signal transduction path-
way that is engaged following TLR2 occupancy is affecting
an early event in the replicative cycle of HIV-1 (i.e. prior
to reverse transcription or integration). In an attempt to
shed light on the exact mechanism(s) by which TLR2 trig-
gering can increase HIV-1 productive infection of IM-
MDDCs, we performed viral entry assays. We found thatRetrovirology 2009, 6:42 http://www.retrovirology.com/content/6/1/42
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internalization of HIV-1 within IM-MDDCs was aug-
mented upon treatment with both TLR2 and 4 agonists.
This observation was unexpected in light of the TLR2-
mediated secretion of CCR5-binding chemokines. How-
ever, it is possible MIP-1α, MIP-1β and RANTES could be
released later than 2 hours following treatment with
Pam3Csk4.
With regard to the TLR2-mediated enhancement in virus
entry, several hypotheses can be proposed. Previous stud-
ies have revealed that HIV-1 entry into DCs can result
either in cytosolic delivery that leads to productive infec-
tion [40,41], preservation into intracellular vesicles in an
infectious state for a subsequent transmission through the
virological synapse [17,42,43], or degradation by lyso-
somal enzymes in the endosomal compartments [44]. It
can be hypothesized that the route of virus entry is
affected upon TLR2 triggering. Knowing that the vast
majority of viruses entering DCs is degraded rapidly (i.e.
up to 95%) [44,56,64-66], it is possible that TLR2 stimu-
lation increases the overall percentage of virions that can
evade the degradation process by a yet to be defined
mechanism. Alternatively, it can also be postulated that
TLR2 triggering prior to virus exposure favors HIV-1 entry
through a pH-independent fusion of viral and cellular
membranes. It is known that this mechanism of HIV-1
internalization into target cells results in productive infec-
tion [40,41,67]. Interestingly, a previous study has shown
that TLR2 engagement by a bacterial product results in
recruitment of this pattern-recognition receptor within
specialized microdomains called lipid rafts [68]. The lat-
eral diffusion of TLR2 inside lipid rafts might result in a
more efficient virus entry through such specific microdo-
mains, which are recognized as a significant portal of
entry for a broad range of pathogens including HIV-1 [69-
73]. The possibility that TLR2 triggering is positively
affecting the early steps of HIV-1 infection in IM-MDDCs
is confirmed by quantitative measurements of reverse
transcripts and integrated viral DNA copies. The negative
impact of LPS on the most proximal events in HIV-1 rep-
licative cycle has been confirmed by the quantitative real-
time PCR test. These results are expected since type-I IFNs
have been shown to exert a paracrine effect on virus infec-
tion by promoting RNA degradation and also by increas-
ing the level of the restriction factor APOBEC3G [74-78].
Altogether our data suggest that a brief treatment of IM-
MDDCs with LPS (i.e. 2 hours) is sufficient to induce the
release of type-I IFNs that will prevent productive HIV-1
infection of this cell population.
We have also performed flow cytometry analyses to mon-
itor CD4 and CCR5 expression following a treatment for
2 hours with TLR2 and 4 agonists but not in response to
TLR5, 7 and 9 ligands based on the absence of a significant
and reproducible effect of those agonists on HIV-1 infec-
tion and viral transmission. Our observations indicate
that engagement of TLR2 and 4 down-regulates expres-
sion of both CD4 and CCR5 (data not shown). These
results are not surprising given that one of the earliest
responses to TLR agonists is an increase in membrane
turnover and macropinocytosis [62]. However the TLR2-
and 4-mediated reduced expression of CD4 and CCR5
cannot explain the opposite effects of these two ligands
with regard to HIV-1 replication in IM-MDDCs cultured
alone. Although it is clear that expression levels of HIV-1
receptor and coreceptors on the surface of DCs can affect
virus entry, other factors can also modulate the life cycle
of HIV-1 in DCs (e.g. distribution of viral receptor/core-
ceptors in some specific membrane microdomains, virus
entry at the cell membrane or via endosomes, efficiency of
reverse transcription and integration processes, modula-
tion of restriction factors, etc.). Additional experiments
are needed to solve this issue.
Under physiological conditions, immature mDCs are
localized in mucosa-like genital and intestinal tracts and
act as sentinels to prevent host invasion by certain patho-
gens. Upon a physical contact with an invader carrying
PAMPs, immature mDCs become activated and migrate to
the most proximal lymph nodes to prime CD4+ T cells.
The recognition of PAMPs by TLRs triggers intracellular
signalling pathways, which culminate in secretion of
proinflammatory cytokines, chemokines and type-I IFNs
and maturation of DCs [79]. The genital mucosa is often
in contact with external pathogens like Neisseria gonor-
rhoeae, Chlamydia trachomatis and  Treponema pallidum,
which respectively cause gonorrhea, chlamydial infection
and syphilis. Those infections can damage the epithelial
barrier and cause microbial translocation leading ulti-
mately to inflammation and activation of mDCs and mac-
rophages. In steady-state, resident flora of the vaginal
mucosa is constituted primarily of lactobacilli that con-
tribute to the equilibrium of the vagina flora by inhibiting
harmful bacteria. However, when this equilibrium is bro-
ken (often following a pH decrease), the amount of lacto-
bacilli is reduced and pathogenic bacteria will prevail.
This phenomenon is common and results in a pathologi-
cal condition called bacterial vaginosis (BV) [80]. This
type of vaginosis is the most widespread, and about 50%
of women are susceptible to this particular type of infec-
tion. It should be noted that BV is associated with an
increased risk for contracting HIV-1 infection and several
other sexually transmitted infections, including herpes
simplex virus type 2 [81-83]. Moreover, BV is associated
with increased levels of proinflammatory cytokines (e.g.
IL-1β and IL-8) and these cytokines induce the secretion
of other proinflammatory cytokines or recruit other
immune cells, thus possibly increasing the number ofRetrovirology 2009, 6:42 http://www.retrovirology.com/content/6/1/42
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cells permissive for HIV-1 infection [84,85]. Knowing
this, it can be hypothesized that such bacteria-derived TLR
ligands as well as others pathogen-encoded TLR agonists
can modulate HIV-1 propagation by mDCs.
Conclusion
In summary, this work provides new insights into the
complex interconnections between HIV-1 and DCs. Our
results reveal that some members of the TLR family (i.e.
TLR2 and 4) can modulate the multifaceted interactions
between HIV-1 and DCs.
Methods
Antibodies and reagents
Anti-phospho-IκBα and anti-IκBα were purchased from
Cell Signaling (Beverly, Massachussets, USA), whereas
anti-actin was obtained from Santa Cruz Biotechnology
Inc. (Santa Cruz, California, USA). Hybridomas produc-
ing 183-H12-5C and 31-90-25, two antibodies recogniz-
ing different epitopes of the HIV-1 major viral core
protein p24, were supplied by the AIDS Repository Rea-
gent Program (Germantown, Maryland, USA) and ATCC
(Manassas, Virginia, USA), respectively. Antibodies
obtained from these cells were purified using mAbTrap
protein G affinity columns according to the manufac-
turer's instructions (Amersham Pharmacia Biotech, Piscat-
away, New Jersey, USA). Pam3Csk4 (a synthetic
tripalmitoylated lipopeptide that mimics the acylated
amino terminus of bacterial lipoproteins) (TLR2 agonist),
lipoteichoic acid (LTA) from Staphylococcus aureus (a puri-
fied bacterial component) (TLR2 agonist), ultra-purified
lipopolysaccharide (LPS) (a purified bacterial compo-
nent) (TLR4 agonist), flagellin (a purified bacterial com-
ponent) (TLR5 agonist), R837 (an imidazoquinoline
compound that mimics single-stranded RNA) (TLR7 ago-
nist) and purified E. coli DNA (a purified bacterial compo-
nent) (TLR9 agonist) were all purchased from InvivoGen
(San Diego, California, USA). The anti-HIV-1 compound
EFV was obtained through the AIDS Repository Reagent
Program. IL-4 was purchased from R&D Systems (Minne-
apolis, Minnesota, USA) and GM-CSF was a kind gift from
Cangene (Winnipeg, Massachussets, USA). The soluble
vaccinia virus-encoded recombinant protein B18R was
purchased from eBioscience (San Diego, CA). Phytohe-
magglutinin-L (PHA-L) and recombinant human IL-2
(rhIL-2) were obtained from Sigma (St-Louis, Missouri,
USA) and AIDS Repository Reagent Program, respectively.
Cells
Human embryonic kidney 293T cells were cultured in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% foetal bovine serum (FBS) (Wisent, St-
Bruno, QC). HEK-Blue™ IFNα/β cells were purchased
from InvivoGen (San Diego, CA) and cultured in DMEM
supplemented with 10% FBS, zeocin (100 μg/ml) and
blasticidin (10 μg/ml). Autologous CD4+ T cells were iso-
lated using a negative selection kit according to the man-
ufacturer's instructions (Stem Cell Technologies Inc.,
Vancouver, BC). Purified CD4+ T cells were cultured for
five days in RPMI-1640 medium supplemented with 10%
FBS before their activation with PHA-L (1 μg/ml) and
rhIL-2 (30 U/ml) for two days. Monocytes (CD14+) were
purified from freshly isolated peripheral blood mononu-
clear cells by immunomagnetic positive selection using
the MACS CD14 micro beads kit (Stem Cell Technologies
Inc). Purified CD14+ cells were cultured in RPMI-1640
medium supplemented with 10% FBS, GM-CSF (1000 U/
ml) and IL-4 (200 U/ml) for 7 days to obtain IM-MDDCs
as previously described [86].
Plasmids and production of viral stocks
pNL4-3 [87] and pNL4-3/Balenv [88] are full-length infec-
tious molecular clones of HIV-1. In pNL4-3Balenv, the env
gene of the X4 (T)-tropic NL4-3 strain has been replaced
with that of the R5 (macrophage)-tropic Bal strain.
Recombinant luciferase-expressing single-cycle pseudo-
typed HIV-1 particles were made upon co-transfection of
293T cells with pNL4-3Luc+E- (obtained from the AIDS
Repository Reagent Program) and pHCMV-G as described
previously [89]. The latter molecular construct codes for
the broad-host-range vesicular stomatitis virus envelope
glycoprotein G (VSV-G) under the control of the human
cytomegalovirus promoter [90]. Progeny viruses were also
produced upon acute infection of purified CD4+ T cells for
7 days with the R5-tropic clinical HIV-1 isolate 93TH054
(obtained from the AIDS Repository Reagent Program).
The virus-containing supernatants were filtered through a
0.22 μm cellulose acetate syringe filter and normalized for
virion content using a homemade p24 test. In this enzy-
matic assay, 183-H12-5C and 31-90-25 antibodies are
used in combination to quantify p24 levels [91]. For
experiments aimed at quantifying reverse transcription
products and integrated viral DNA copies, NL4-3/Balenv-
containing supernatants were filtered through a 0.22 μm
cellulose acetate syringe filter, treated with DNase I
(Roche) for 45 min at room temperature to prevent viral
DNA carryover [92] and finally ultracentrifuged to elimi-
nate enzyme in an Optima L-90K Beckman Coulter appa-
ratus (Fullerton, CA) for 45 min at 28,000 rpm (100,000
× g) in a 70 Ti rotor.
Virus transfer experiments
IM-MDDCs (5 × 104 in 100 μl of culture medium) were
either left untreated or treated with one of the studied TLR
agonists for 2 hours, washed twice and pulsed with virus
preparations (2.5 ng of p24) for 1 hour at 37°C. In some
studies, EFV (25 nM) was added to inhibit direct produc-
tive infection and left for 30 min before pulsing with
viruses. Next, the virus-cell mixture was washed twice with
phosphate-buffered saline (PBS) to remove free virions.Retrovirology 2009, 6:42 http://www.retrovirology.com/content/6/1/42
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For estimating early HIV-1 transfer, IM-MDDCs were co-
cultured with autologous activated CD4+ T lymphocytes at
a 1:2 ratio in complete RPMI-1640 medium supple-
mented with rhIL-2 (30 U/ml) in 96-well flat-bottom tis-
sue culture plates in a final volume of 200 μl. Cell-free
supernatants (half of the medium) were harvested at day
2, 3 and 6 following initiation of the co-culture and kept
frozen at -20°C. Virus production was estimated by meas-
uring p24 levels in such culture supernatants.
Virus infection studies
IM-MDDCs (5 × 104 in 100 μl of culture medium) were
either left untreated or treated with a TLR agonist for 2
hours, washed twice and pulsed with virus preparations
(2.5 ng of p24) for 1 hour at 37°C. In some studies, EFV
(25 nM) was added to inhibit direct productive HIV-1
infection and left for 30 min before pulsing with viruses.
Next, the virus-cell mixture was washed twice with PBS to
remove free virions. Inverse kinetic was also performed
where IM-MDDCs were first infected for 1 hour and then
stimulated with a TLR2 agonist. Thereafter, IM-MDDCs
were cultured in complete RPMI-1640 medium in 96-well
flat-bottom tissue culture plates in a final volume of 200
μl. Supernatants (half of medium) were harvested either
at day 3, 6 and 9 (infection with NL4-3/Balenv) or 5, 8 and
12 (infection with 93TH054) following HIV-1 infection
and kept at -20°C until assayed for p24 contents. For stud-
ies aimed at defining the contribution of type-I IFNs, the
same experimental procedure was followed except that
the medium was supplemented with B18R (0.1 μg/ml). In
some experiments, IM-MDDCs were infected with VSV-G
pseudotyped reporter virus (2.5 ng of p24) for 2 hours
and washed to remove free virions. Next, the virus-cell
mixture was cultured for 48 hours before stimulation with
the TLR2 agonist for 2 hours. Cells were then washed and
luciferase activity was monitored 48 hours later.
Quantification of IFN /
IM-MDDCs were either left untreated or treated for 6
hours with all studied TLR agonists. Next, levels of IFNα/
β in cell-free supernatants were determined through the
use of HEK-Blue™ IFNα/β cells according to the manufac-
turer's protocol (InvivoGen). These cells allow the detec-
tion of bioactive IFNα and IFNβ by monitoring the
activation of the ISGF3 pathway. HEK-Blue™ IFNα/β cells
are stably transfected with a SEAP promoter gene under
the control of the IFNα/β-inducible ISG54 promoter.
Stimulation of these cells with type-I IFNs activates the
JAK/STAT/ISGF3 pathway and induces subsequently the
secretion of SEAP in the supernatant. A standard curve of
IFNα ranging from 1 to 250 Units/ml was used to quantify
the amounts of type-I IFNs released in the culture
medium.
Electrophoresis and western blotting
IM-MDDCs (5 × 106) were either left untreated or treated
with a TLR agonist for 0, 2, 5, 15 and 30 min. For each
time point, the equivalent of 2.5 × 104 cells was trans-
ferred into 2× sample buffer. Samples were boiled for 7
min and kept at -20°C until subjected to a western blot
analysis. In brief, samples were loaded onto sodium
dodecyl sulphate (SDS)-10% polyacrylamide gel electro-
phoresis (PAGE). Proteins were then transferred to Immo-
bilon membranes (Millipore Corporation, Bedford,
Massachussets, USA). Immunoblotting was performed
first with anti-phospho-IκBα (dilution 1:1000) overnight
at 4°C. Next, the membrane was stripped and blotted
with anti-IκBα (dilution 1:1000) overnight at 4°C. To
measure the amount of protein loaded in the gel, the
membrane was stripped again and immunoblotted with
anti-actin (dilution 1:5000) for 1 h at room temperature.
Proteins were detected with an enhanced chemilumines-
cence reagent (Pierce) followed by exposure to Kodak
films.
Bio-Plex cytokine assay
A commercial Bio-Plex cytokine test that can detect and
quantify 7 different cytokines (i.e. IL-1β, IL-6, TNFα, IL-
12p70, MIP-1α, MIP-1β and RANTES) through the use of
the Luminex®  100™ apparatus (Luminex Corporation,
Austin, TX) was purchased from Bio-Rad Laboratories
(Mississauga, ON). The Luminex technology is a bead
array cytometric analyzer designed to study numerous
analytes simultaneously by using spectrally distinct beads
in a single well of a microtiter plate, using very small sam-
ple volumes (i.e. as little as 25 μl). Briefly, IM-MDDCs
were either left untreated or treated for 8 and 24 hours at
37°C with the following stimuli: Pam3Csk4 (5 μg/ml),
LPS (0.1 μg/ml), flagellin (5 μg/ml), R837 (5 μg/ml) and
unmethylated DNA (5 μg/ml). Quantification was
achieved by measuring concentrations of the studied
cytokines and chemokines in cell-free supernatants
according to the manufacturer's instructions.
Virus entry assay
IM-MDDCs (4.5 × 106 in 1.8 ml of culture medium) were
either left untreated or treated with the TLR2 or 4 agonist
for 2 hours and washed twice. Then, cells (5 × 105 in 200
ul of complete culture medium) were pulsed with HIV-1
(12.5 ng of p24) for 15, 30 and 60 min at 37°C. The virus-
cell mixture was washed extensively with PBS and treated
with trypsin to remove uninternalized virions. Finally,
cells were lysed with 250 μl of lysis buffer (HEPES 20 mM,
NaCl 150 mM and Triton 0.5%). Viral entry was estimated
by measuring p24 levels in lysed cells.Retrovirology 2009, 6:42 http://www.retrovirology.com/content/6/1/42
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Quantification of reverse transcription products and 
integrated viral DNA copies
IM-MDDCs (1 × 106) were either left untreated or treated
with the TLR2 or TLR4 agonist for 2 hours and pulsed with
DNaseI treated NL4-3/Balenv (100 ng of p24 per 1 × 106
cells) for 1 hour and washed twice. IM-MDDCs were cul-
tured for 6, 24 and 48 hours. Then, genomic DNA was
extracted using the DNeasy Blood & Tissue Kit (QIAGEN,
Mississauga, ON). Integrated proviral DNA copies were
quantified using a combined Alu-HIV-1 PCR and real-
time PCR assay as described by Suzuki and colleagues
[93]. Briefly, genomic DNA (100 ng) was first amplified
with an Alu-sequence-specific sense primer and HIV-1-
specific antisense primer (i.e. M661) [94]. Next, 5 μl of
25-fold diluted PCR products were subjected to a real-
time PCR assay in 25 μl reaction containing 2× TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster
City, CA), 2 μM of the sense primer M667, 2 μM of the
antisense primer AA55, and 0.3 μM of the TaqMan probe
HIV-5'-carboxyfluorescein (Biosearch Technologies,
Novato, USA). The cycling conditions included a hot start
(50°C for 2 min and 95°C for 10 min), followed by 40
cycles of denaturation (95°C for 1 min) and extension
(63°C for 1 min) with end point acquisition. NL4-3/
Balenv DNA was used for the standard curve (i.e., from
469 to 30,000 copies). HIV-1 standards contain 1 ng of
DNA from uninfected cells as carrier. For quantification of
early and late reverse transcripts, 25 ng of DNA were sub-
jected to a real-time PCR assay in 25 μL reaction contain-
ing 2× TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA), 1 μM of the sense primer
M667, 1 μM of the antisense primer M661 (late RT) or
AA55 (total RT), and 0.3 μM of the TaqMan probe HIV-5'-
carboxyfluorescein (Biosearch Technologies, Novato,
USA) [39]. NL4-3Balenv DNA was used for the standard
curve (i.e. from 235 to 15,000 copies). HIV-1 standards
contained 25 ng of DNA from uninfected cells as carrier.
The amounts of early reverse transcripts were obtained by
subtracting the late reverse transcripts from the total
reverse transcripts.
Statistical analysis
Statistical analyses were carried out according to the meth-
ods outlined in Zar and Sokal and Rohlf. Briefly, homo-
scedasticity was determined using the variance ratio test
and the means were compared using a single factor
ANOVA followed by appropriate post hoc multiple com-
parisons (Tukey's or Dunnett's). P values lower than 0.05
were considered highly significant. For the percentages of
inhibition, statistical analysis was performed by using arc-
sin transformation followed by a Student's t-test. Results
from three or more experiments were always used for
these analyses. Computations were carried out using
GraphPad PRISM ® version 3.03 statistical software.
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